^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
long-acting Erwinia asparaginase (JZP341)
i
Other names: JZP-341, JZP341, PF745
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jazz, Ligand
Drug class:
Aspartate-ammonia ligase inhibitor, Amidohydrolase stimulant
Related drugs:
6ms
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=12, Terminated, Jazz Pharmaceuticals | Trial completion date: Nov 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2024 --> Apr 2024; The study was terminated based on a business decision by the Sponsor.
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
long-acting Erwinia asparaginase (JZP341)
9ms
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting | N=88 --> 12 | Trial completion date: Nov 2027 --> Nov 2024 | Trial primary completion date: Nov 2027 --> Nov 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
long-acting Erwinia asparaginase (JZP341)
1year
Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) (ASH 2023)
We reported in vitro and in vivo depletion of Gln induced by long-acting Erwinia asparaginase, PegC, inhibited proliferation of complex karyotype (CK) AML and synergistically enhanced the antiapoptotic activity of Ven-mediated antagonism of Bcl-2 by decreasing the expression of proteins such as Mcl-1, whose translation is cap-dependent...Pt 31 (post-alloHSCT relapsed AML with FLT3-ITD) who had persistent disease after gilteritinib achieved an MRD-negative CRi, pending 2nd alloHSCT... VenPegC is a novel regimen that can induce complete remission in some heavily pretreated R/R AML patients, even with previous exposure to Ven. Pts with RUNX1 mutation, whose translation depends on pheIF4E, may benefit further from this regimen.
P1 data • IO biomarker
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • MCL1 (Myeloid cell leukemia 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • CSF3R (Colony Stimulating Factor 3 Receptor) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
TP53 mutation • NRAS mutation • RUNX1 mutation • RAS mutation • PTPN11 mutation • MCL1 expression • CSF3R mutation
|
Venclexta (venetoclax) • Xospata (gilteritinib) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • long-acting Erwinia asparaginase (JZP341)
almost2years
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=88, Recruiting, Jazz Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
long-acting Erwinia asparaginase (JZP341)
almost2years
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=88, Not yet recruiting, Jazz Pharmaceuticals
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
long-acting Erwinia asparaginase (JZP341)
Share via
